STOCK TITAN

Stryker Corp Stock Price, News & Analysis

SYK NYSE

Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.

Stryker Corporation (NYSE: SYK) is a global innovator in medical technologies, driving advancements in orthopedics, surgical equipment, and digital healthcare solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on SYK's latest developments, financial performance, and strategic initiatives.

Access authoritative information on earnings announcements, product innovations, regulatory milestones, and acquisition activity. Our curated collection ensures timely access to press releases covering SYK's neurotechnology systems, AI-assisted surgical tools, and minimally invasive treatment solutions that shape modern healthcare.

Key updates include quarterly financial results, FDA clearances for medical devices, partnership announcements, and insights into SYK's expanding digital health ecosystem. Stay informed about developments in robotic-assisted surgery platforms, smart operating room integrations, and global market expansion efforts.

Bookmark this page for streamlined access to verified SYK updates. Check regularly for objective reporting on how Stryker's innovations in joint replacement technologies, emergency care equipment, and healthcare IT solutions continue impacting patient outcomes worldwide.

Rhea-AI Summary

VB Spine completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France on January 6, 2026, expanding its global manufacturing footprint.

The Cestas site, including its people, infrastructure, and processes, will anchor VB Spine's worldwide manufacturing strategy and support expanded medical education and training programs in Europe. Employees transitioned from Stryker to VB Spine and manufacturing operations continue without interruption. Integration planning is underway to align systems, quality, and supply chain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.05%
Tags
-
Rhea-AI Summary

Stryker (NYSE:SYK) will report fourth quarter and full year 2025 financial results on Thursday, January 29, 2026. A press release with summary financial information for the period ended December 31, 2025 will be issued at approximately 4:05 p.m. ET and posted to the company's press releases page.

Stryker will host a live webcast at 4:30 p.m. ET on January 29, 2026 to discuss results; the webcast is accessible on the company's Events & Presentations page and an archive will be available about two hours after the call ends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
earnings date
-
Rhea-AI Summary

Stryker (NYSE:SYK) announced a quarterly dividend of $0.88 per share, payable January 30, 2026 to shareholders of record at the close of business on December 31, 2025. The Board said the payout represents a 4.8% increase versus both the prior year and the previous quarter. Management framed the raise as consistent with the company’s capital allocation priorities and confidence in future financial performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
dividends
Rhea-AI Summary

Stryker (NYSE:SYK) announced Spencer Stiles will become President and Chief Operating Officer effective January 1, 2026. Stiles, a 27-year Stryker veteran and current Group President of Orthopaedics and Spine since 2019, will lead global businesses, strategy, and mergers and acquisitions. Dylan Crotty will be promoted to Group President, Orthopaedics; Crotty has 27 years at Stryker and currently serves as President, Instruments.

The appointments emphasize internal succession, operational continuity, and leadership experience across Orthopaedics, MedSurg, and Neurotechnology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Summary

Stryker (NYSE:SYK) reported third quarter 2025 results: net sales $6.06B (+10.3% reported, +9.6% constant currency) and organic net sales +9.5%. MedSurg & Neurotechnology sales rose 14.4%; Orthopaedics rose 3.9% (pro forma Orthopaedics +12.5% excluding a divestiture). Reported EPS was $2.22 (+2.8%) and adjusted EPS was $3.19 (+11.1%). Adjusted operating margin expanded 90 bps to 25.6%; reported operating margin was 18.7%. Management raised full-year 2025 guidance to organic net sales growth 9.8–10.2% and adjusted EPS of $13.50–$13.60. The results reflect acquisition activity, higher amortization, and increased long-term debt linked to recent transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary

Stryker (NYSE:SYK) will showcase expanded trauma solutions at the Orthopaedic Trauma Association Annual Meeting, October 15–18, 2025 in Phoenix (booth #601).

The company highlighted extensions to its Pangea and T2 Alpha nailing and plating platforms, including a new T2 Alpha Humeral nail designed for simplicity and streamlined humeral fixation, plus a novel femur reconstruction fracture system that combines T2 Alpha and Pangea for complex native and periprosthetic femur fractures. Stryker emphasizes simplified instrumentation, enhanced stability, and workflow efficiency, and will offer hands-on demonstrations and expert conversations at its booth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
Rhea-AI Summary

Stryker (NYSE:SYK) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will release its Q3 2025 earnings press release at 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET.

The financial results will cover the quarter ending September 30, 2025. Investors can access the webcast through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary

Stryker (NYSE:SYK) announced the launch of its Incompass™ Total Ankle System at the 2025 AOFAS Annual Meeting in Savannah, Georgia. The FDA-cleared system is designed for patients with end-stage ankle arthritis, featuring an innovative implant with an enhanced instrument platform.

The system builds on Stryker's legacy designs, Infinity and Inbone, which have demonstrated five-year survivorship rates of 98% or higher. Key features include 3D-printed porous metal components for early bony ingrowth, intraoperative flexibility, and reduced procedural complexity. The development leveraged SOMA technology and analysis of over 80,000 Prophecy scans and 100,000 total ankle cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
News
Rhea-AI Summary

Stryker (NYSE:SYK), a leading medical technology company, has announced it will host an Investor Day on November 13, 2025, at 2:30 p.m. Eastern Time. The event will take place in Mahwah, New Jersey.

Investors and interested parties can access the event through a live audio webcast on Stryker's website. For those unable to attend live, a replay of the session will be made available in the Investor Relations section of www.stryker.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
Rhea-AI Summary

Stryker (NYSE:SYK), a leading medical technology company, announced its participation in the upcoming 2025 Wells Fargo Securities Healthcare Conference. The event will take place at the Encore Boston Harbor on September 4, 2025.

Andy Pierce, Group President of MedSurg and Neurotechnology, and Jason Beach, Vice President of Finance and Investor Relations, will engage in a Fireside Chat at 2:15 PM ET. Investors can access both the live webcast and replay through Stryker's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences

FAQ

What is the current stock price of Stryker (SYK)?

The current stock price of Stryker (SYK) is $367.54 as of January 11, 2026.

What is the market cap of Stryker (SYK)?

The market cap of Stryker (SYK) is approximately 140.6B.
Stryker Corp

NYSE:SYK

SYK Rankings

SYK Stock Data

140.56B
361.55M
5.36%
81.68%
1.09%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PORTAGE